A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
作者： S Dirmesropian , JG Wood , CR MacIntyre , AT Newall
DOI: 10.1080/21645515.2015.1011954
关键词: Childhood vaccination 、 Pediatrics 、 Cost–benefit analysis 、 Economic evaluation 、 Cost effectiveness 、 Herd immunity 、 Medicine 、 Gerontology 、 Pneumococcal conjugate vaccine
摘要: The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and being considered wider use in many countries. In order to identify the strengths limitations of existing economic evaluation studies PCV13 adults elderly a literature review was conducted. majority identified (9 out 10) found that cost-effective and/or elderly. However, these results were based on assumptions could not always be informed by robust evidence. Key uncertainties included efficacy against non-invasive pneumonia herd immunity effect childhood vaccination programs. Emerging trial evidence from Netherlands offers ability parameterize future evaluations with empirical data. it important estimates are used thoughtfully when they transferred other settings.
sci-hub.se 参考文章(38)
Alicia M Fry, Elizabeth R Zell, Anne Schuchat, Jay C Butler, Cynthia G Whitney, Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. ,vol. 21, pp. 303- 311 ,(2002) , 10.1016/S0264-410X(02)00451-6
Kenneth J. Smith, Mary Patricia Nowalk, Mahlon Raymund, Richard K. Zimmerman, Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine. ,vol. 31, pp. 3950- 3956 ,(2013) , 10.1016/J.VACCINE.2013.06.037
Helen E. Baxendale, Sheila M. Keating, Marina Johnson, Jo Southern, Elizabeth Miller, David Goldblatt, The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly Vaccine. ,vol. 28, pp. 4763- 4770 ,(2010) , 10.1016/J.VACCINE.2010.04.103
I. Ridda, C.R. MacIntyre, R. Lindley, Z. Gao, J.S. Sullivan, F.F. Yuan, P.B. McIntyre, Immunological responses to pneumococcal vaccine in frail older people Vaccine. ,vol. 27, pp. 1628- 1636 ,(2009) , 10.1016/J.VACCINE.2008.11.098
C. Raina MacIntyre, Iman Ridda, Zhanhai Gao, Aye M. Moa, Peter B. McIntyre, John S. Sullivan, Thomas R. Jones, Andrew Hayen, Richard I. Lindley, A Randomized Clinical Trial of the Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine Compared to 23-Valent Polysaccharide Vaccine in Frail, Hospitalized Elderly PLoS ONE. ,vol. 9, pp. e94578- ,(2014) , 10.1371/JOURNAL.PONE.0094578
Jane E. Sisk, William Whang, Jay C. Butler, Vishnu-Priya Sneller, Cynthia G. Whitney, Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race Annals of Internal Medicine. ,vol. 138, pp. 960- 968 ,(2003) , 10.7326/0003-4819-138-12-200306170-00007
Bo-Hyun Cho, Charles Stoecker, Ruth Link-Gelles, Matthew R. Moore, Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. ,vol. 31, pp. 6011- 6021 ,(2013) , 10.1016/J.VACCINE.2013.10.024
Derek Weycker, Reiko Sato, David Strutton, John Edelsberg, Mark Atwood, Lisa A. Jackson, Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years Vaccine. ,vol. 30, pp. 5437- 5444 ,(2012) , 10.1016/J.VACCINE.2012.05.076
Kenneth J. Smith, Angela R. Wateska, Mary Patricia Nowalk, Mahlon Raymund, J. Pekka Nuorti, Richard K. Zimmerman, Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine JAMA. ,vol. 307, pp. 804- 812 ,(2012) , 10.1001/JAMA.2012.169
Roberto Pradas, Angel Gil de Miguel, Alejandro Álvaro, Ruth Gil-Prieto, Reyes Lorente, Cristina Méndez, Pablo Guijarro, Fernando Antoñanzas, Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model BMC Infectious Diseases. ,vol. 13, pp. 175- 175 ,(2013) , 10.1186/1471-2334-13-175